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INTRODUCTION 
In past few decades attention has been focused on 
development of vesicular drug delivery system. Nowadays, 
vesicles as a carrier system have become the vesicles of 
choice in drug delivery and lipid vesicles are established to 
be valuable in immunology, membrane biology, and 
diagnostic technique, an d most importantly in genetic 
engineering. Lipids are referred to a group of naturally 
occurring molecules which include fats, waxes, sterols, fat-
soluble vitamins (such as vitamins A, D, E, and K), as well 
as mono-glycerides, triglycerides, phospholipids. Lipids 
may be broadly defined as hydrophobic or amphiphilic 
small molecules; the amphiphilic nature of some lipids 
allows them to form structures such as that of 
vesicles. 
1
 Therefore, researchers recognize the potential of 
the lipids for delivering soluble materials for extended 
periods. 
2
 Vesicles are unilamellar or multilamellar 
spheroid structures composed of lipid molecules 
assembled into bilayers, Because of their capacity to carry 
a number of drugs, vesicular delivery systems have been 
widely investigated for their prospective application in 
pharmaceutics such as drug delivery 
3-5
 for drug 
targeting, 
6
 forcontrolled release, 
7
 or for increasing 
solubility. 
8
  
Emulsomes is a novel lipoidal vesicular system with an 
internal solid fat core surrounded by a phospholipid 
bilayer. Structure of emulsomes is shown in [Figure1]. 
Emulsomal formulations composed of solid lipid core 
material and stabilized by cholesterol and soya lecithin. 
The drug is loaded followed by sonication to produce 
emulsomes of small size. 
9
 The polymer used for core 
material should be solid at room temperature (25°C).
10
 The 
high soya lecithin concentration stabilized the emulsomes 
in form of O/W emulsion. 
11
 These fat cored lipid particles 
are dispersed in an aqueous phase. These systems are often 
prepared by melt expression or emulsion solvent diffusive 
extraction. 
 
Figure 1: Structure of emulsome 
Emulsome represents lipid-based drug delivery systems 
with broad variety of therapeutic applications particularly 
for drugs that are poor aqueous soluble. 
12
 Emulsomes 
consist of microscopic lipid assembly with a polar core, 
which contains water insoluble drugs in the solution form 
without requiring any surface active agent or co-solvent. 
Beside the other vesicular formulations, emulsomes are 
much stabilized and nano range vesicles. It is a new 
emerging delivery system and therefore could play a 
fundamental function in the effective treatment of life-
threatening viral infections and fungal infections such as 
hepatitis, HIV, Epstein-Barr virus, leishmaniasis, etc. 
appear promising for the treatment of visceral 
leishmaniasis specifically and hepato-splenic candidiasis. 
9-
11
 Furthermore, in systemic fungal infections, the systems 
can be used for rapid loading of reticuloendothelial system 
organs with the incorporated drug for the complete 
eradication of the intracellular pathogens. Emulsomes 
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could be utilized in order to improve oral controlled 
delivery of drug, vaccine, and bioamcromolecules. It is due 
to the fact that they are nano sized in range and could be 
utilized for the intravenous route. Moreover, emulsomes 
could represent a more economical alternative to current 
commercial lipid formulations for the treatment of viral 
infections and fungal infections. Emulsomes provide a 
controlled and sustain release of drug. In comparison to the 
liposomes, emulsomes provide a prolong release of drug 
upto 24 hours, whereas liposomes have shown release upto 
6 hours. 
12-14
 Emulsomes are nano size range in 
comparison to other vesicular delivery system such as 
niosomes, pharmacosomes, and ethosomes. Due to the 
reduced size they can be used to enhance bioavailability to 
drug and as the best carrier for the intravenous drug 
delivery as well as oral drug delivery. 
 
Advantages of emulsomes  
Emulsomes defend drug from harsh gastric environment of 
stomach before oral administration because the drug is 
enclosed in the triglyceride lipid core. This hypothesis 
could be supported by the fact that gastric pH and gastric 
enzymes are unable to hydrolyze triglycerides. 
Emulsomes increase the solubility and bioavailability of 
poorly aqueous soluble drugs. They are composed of 
triglycerides and form micelles or are organized as lipid 
bilayers with the hydrophobic tails lined up against one 
another and the hydrophilic head-group facing the water 
on both sides. These unique features make phospholipids 
most suitable to be used as excipients for poorly water 
soluble drugs. 
Emulsomes are composed of lipid core. Lipids are used to 
develop oral controlled delivery of drug. The wide spread 
adoption of lipid based strategies for enhancing drug 
exposure is limited. 
Emulsomes are economical alternative to current 
commercial lipid formulations because they reduce the 
dosing frequency of drug. 
Emulsomes-based system showed excellent potential for 
targeting. The formulations could significantly modify 
providing prolonged action at comparatively low drug 
doses thereby reduction in the toxicity problem due to 
complimentary localization of the drug in target cells. 
They provide significantly modify the pharmacokinetics of 
drugs. 
Also, they resist development of multi drug resistance, 
often associated with over expression of a cell membrane 
glycoprotein, which cause efflux of the drug from the 
cytoplasm and results in an ineffective drug concentration 
inside the cellular compartment. 
 
Mechanism of emulsome sabsorption  
Emulsomes have structural similarity with the 
chylomicrons (natural lipoprotein of the body) and 
consequently expected to mimic these lipoproteins in 
behavior. These diminutive lipids like particles are 
frequently taken through endogenous lipid absorption 
mechanism through enterocytes of GIT tract. 
14
 Intestinal 
absorption of long-chain triglyceride from enterocytes is a 
complex incident that includes the co-ordination of 
synthesis of apolipoproteins and lipids and their 
intracellular assembly into mature lipid-containing 
particles. 
15
 The major digestive products of triglyceride 
are monoglycerides and free fatty acids. These are 
absorbed into the enterocytes via passive diffusion and 
transported within the enterocyte to the endoplasmic 
reticulum (ER), where biosynthesis of complex lipids to 
form triglyceride takes place. 
16
 The precursors of 
chylomicrons, termed prechylomicrons, are synthesized in 
the ER and Golgi apparatus. Lipoproteins are made in the 
ER and then transported to the Golgi. The chylomicrons 
then migrate to the lateral membrane of enterocytes and 
are exocytosed, and the triglyceride-rich lipoproteins are 
discharged into the intercellular space. 
17
 Lipid-based 
excipients can influence oral absorption via various 
physiological effects such as retarded gastric 
emptying, 
18
 stimulating bile flow, and secretion of 
pancreatic juice increasing the membrane lipid fluidity or 
acting directly onto enterocytes-based drug transport and 
disposition. 
19-21
  
 
Emulsomal formulation  
Lipidcore 
An essential component of emulsomes is an internal 
hydrophobic core or lipid core comprises lipid, which 
exhibits solid or lipid crystal phase or mixed solid and 
liquid crystal phase at room temperature (25°C). There are 
abundant lipids or lipid like excipients available 
commercially. All of which are collectively called lipids in 
the pharmaceutical field. 
22
 The lipid used may be single or 
mixture of lipids. They are fatty acids and their derivatives 
or substances biosynthetically and functionally related to 
these compounds. 
23-25
 Lipids are generally insoluble in 
water and are often identified by their fatty acid 
composition, melting point, and hydrophilic-lipophilic 
balance (HLB). Lipids with low HLB and high melting 
point are suitable for sustained release. Whereas, the semi-
solid excipients and those with high HLB serve as 
immediate release and bioavailability enhancement 
excipients.
26-29
 Triglycerides which are solid at 25°C are 
found to be appropriate core material because these lessen 
the acceptable storage life of o/w emulsion. The 
triglycerides are used for preparation of emulsome 
composed of un-branched fatty acid with chain length in 
the c-10 to c-18 range. 
30
  
 
 
Antioxidant 
 
The lipid core of emulsome particles of this invention 
optionally may contain one or more antioxidant. The 
preferred antioxidant is a-tocopherol or its derivative, 
which are members of vitamin E family. Other 
antioxidants include butylated hydroxytouline (BHT). 
Antioxidants lessen the formation of oxidative degradation 
products of unsaturated lipids such as peroxides. The need 
of antioxidant may be protected by preparing the lipid core 
form saturatedfattyacid.
30
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Negatively charged particles 
Negatively charged lipid particles such as oleic acid or 
negatively charged phospholipids such as phosphatidic 
acid, phosphatidylinositol, and phosphatidylsterine can be 
imparted to emulsomes to raise the zeta potential of the 
composition, thus stabilizing the particles. Additionally, 
the incorporation of these negatively charged lipids 
compounds in emulsomes result in the formation of 
phospholipids bilayers with opposing charge. 
30
 Thus, 
increasing the loading aqueous compartment formed by the 
phospholipids bilayers surround the lipid core. This effect 
results from the layers aqueous space between the bilayers 
cause electrostatic repulsion between them. Negative 
charge reduces the particles aggregation, 
whichminimizesthecoalescence,floccation,orfusion. 
31
  
 
Surfactants 
Selection of surfactant should be done on the basis of 
Hydrophilic Lipophilic Balance (HLB) value. As HLB is a 
good indicator of the vesicle forming ability of any 
surfactant, HLB number in between 4 and 8 was found to 
be compatible with vesicle formation.
32
 Transition 
temperature of surfactants also affects the entrapment of 
drug in vesicles. Spans with highest phase transition 
temperature provide the highest entrapment for the drug 
and vice versa
33-34
 The drug leaching from the vesicles is 
reduced due to high phase transition temperature and low 
permeability. 
35
 High HLB value of Span 40 and 60 results 
in reduction in surface free energy, which allows forming 
vesicles of larger size and hence large area 
exposedtothedissolutionmedium.
36-38
  
 
Phosphatidylcholine 
Phosphatidyl choline is such a major component of 
lecithin. Phosphatidyl choline has low solubility in water. 
In aqueous solution its phospholipids can form bilayer 
sheets, micelles, or lamellar structures, depending on 
hydration and temperature. This results in a type of 
surfactant that is usually classified as amphipathic. They 
are a major component of biological membranes and can 
be easily obtained from a variety of readily available 
sources such as egg yolk or soya beans. Depending upon 
the source from which they are obtained they are named as 
egg lecithin and soya lecithin. Incorporation of lecithin 
further enhanced the percent drug entrapment to 96.1% 
and leads to vesicles of smaller size due to increase in 
hydrophobicity, which results in reduction of vesicle 
size. 
39
  
 
Cholesterol 
Cholesterol is essential component of emulsomes as 
vesicles. Incorporation of cholesterol influences vesicles 
stability.
40-41 
Concentration of cholesterol plays an 
important role in entrapment of drug in vesicles. 
42-43
 There 
are reports that entrapment efficiency increase with 
increasing cholesterol content. It was observed that with 
very high cholesterol content had a lowering effect on drug 
entrapment to the vesicles. 
44
 This could be due to the fact 
that cholesterol beyond a certain level starts disturbing the 
regular bilayer structure leading to loss of drug 
entrapment. 
45
 Various materials used for emulsomal 
preparation along with their uses are given in [Table 1].
 
 
 
Methods of preparation 
Lipid film formation (Handshaking method) 
In this method surfactants/lipids are casted as layers of 
film form their organic solution using flask rotary 
evaporator under reduce pressure (or by hand shaking) 
and then casted films are dispersed in aqueous 
medium. 
46
 Upon hydration, the lipids swell and peel off 
from the wall of round bottom flask at temperature 
slightly above the phase transition temperature of 
surfactants used for specific period of time (time of 
hydration) with constant mild shaking. The mechanical 
energy is required for the swelling of lipid and dispersion 
of casted lipid film is imparted by manual by manual 
hand shaking or by exposing the film to a steam of water 
saturated nitrogen for 15 minutes followed by swelling in 
the aqueous medium without shaking. Hand shaking 
method produce multi lamellar vesicles (MLV) while non 
shaking method produced large unilamellar vesicles 
(LUVs). Various methods for emulsomal formulations are 
shown in [Figure 2]. 
47 
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Figure 2: Methods of emulsomal formulation
 
 
Reserve phase evaporation 
This technique, so-called 'reverse-phase evaporation' or 
REV method is comprised of two steps. Prepare a water-
in-oil emulsion of phospholipids and buffer in excess 
organic phase. Remove organic phase under reduced 
pressure. The two phases (phospholipids and water) are 
usually emulsified by mechanical methods or by 
sonication. Removal of the organic solvent under vacuum 
causes the phospholipid coated water droplets to come 
together to form a gel-like matrix. Further removal of 
organic solvent, under reduced pressure, causes the gel-
like matrix to form into a paste of smooth consistency. 
This paste is a suspension of LUV. 
48
 Drug entrapment 
efficiencies up to 60-65% can be achieved by this method. 
This method was used to encapsulate both small and large 
molecules. 
49
 The main disadvantage of this method is the 
exposure of drug to be encapsulated to organic solvents 
and to mechanical agitation. In this procedure, 
phospholipids are dissolved in organic solvents such as 
chloroform, isopropylether, or freon. In order to promote 
conditions for good emulsification, it may sometimes be 
required to mix two organic solvents to adjust the density 
to unity that is closer to the density of aqueous phase. 
Biologically active molecules such as enzymes, protein 
pharmaceuticals, and RNA type molecules may undergo 
conformational changes, protein denaturation, or breakage 
of DNA strands due to the harsh conditions of organic 
solvent exposure and mechanical agitation. 
 
High-pressure extrusion technique 
It was demonstrated by several researchers that when 
MLV are repeatedly passed through very small pore 
polycarbonate membranes (0.8 to 1.0 pm) under high 
pressure the average diameter of the vesicles become 
progressively smaller reaching a minimum of 60-80 nm 
after 5-10 passes. As the average size is reduced the 
vesicles tend become unilamellar.
50-52
 Similar results are 
noted by other investigators when MLV were passed 
through a Microfluidizer. Microfluidizer is an instrument 
that forces the feed material under high pressure through a 
narrow orifice. It appears that when MLV are forced 
through the small orifice, layers of bilayers are removed 
from the vesicular structure, as if the layers of onion skin 
are separated when it is peeled. It was also suggested that 
the mechanism of layer separation is only applicable to 
vesicles made with positively charged phospholipids and 
the vesicles that are greater than 70 pm in size.
53
  
 
Sonication method 
Solid lipids, cholesterol, and phosphatidylcholine in 
different molar ratios were taken in a round-bottom flask 
and dissolved in a minimum quantity of chloroform 
containing 3 or 4 drops of methanol. To this solution, an 
accurately weighed quantity of drug was dissolved. The 
organic solvent was evaporated until complete dryness 
under reduced pressure using a rotary evaporator to form a 
thin lipid film on walls of the round bottom flask. 
54-56
 The 
dried film was hydrated with phosphate-buffered saline pH 
7.4 (10 mL) and homogenized by ultrasonication for 15 
minutes at 40% frequency to obtain emulsomes of nano-
size range. 
9,10,14
  
 
Cast film method 
Emulsomes may be prepared by mixing phospholipids and 
triglycerides in a weight ratio range 0.5:1.0 where in the 
triglycerides has a solid to liquid phase transition 
temperature of greater than 25°C. Suspend the mixture in 
an aqueous solution at a temperature below the solid to 
liquid transition temperature otherwise reducing the 
suspension to yield emulsomes. These emulsomes 
comprise a nano-emulsion of liquid particles having a 
mean particle diameter between 10-250 nm usually within 
the range 20 to 180 nm usually and frequency within range 
50-150 nm. The size range is preferably determined on a 
weight percentage basis rather preferably are determined 
on a weight percentage basis rather than a particle number 
basis. Conventionally the lipid component may be volatile 
and chemically un-reactive volatile organic solvent such as 
dichloromethane or diethylether. The solvent is removed 
typically under reduced pressure in a rotary evaporator or 
under stream of inert gas. The resulting lipid film is 
hydrated and dispersed by covering and shaking with an 
aqueous solution. If the drug component were not included 
in the organic solution, they may be added to aqueous 
hydration solution. The lipid suspension or dispersion is 
then sized typically by high shear homogenizer at a 
pressure up to 800 bars. 
30
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 Ethanol injection method 
This method has been reported as one of the alternatives 
used for the preparation of small unilammellar vesicles 
(SUVs). In this method, an ethanol solution of surfactant is 
injected rapidly through a fine needle into excess of saline 
or other aqueous medium. 
57
 Vaporization of ethanol leads 
to the formation of vesicles. In the ethanol injection 
method a narrow distribution of small liposomes (under 
100 nm) can be obtained by simply injecting an ethanolic 
lipid solution in water, i.e. in one step, without extrusion or 
sonication. The ethanol injection method is a suitable 
technique to obtain the spontaneous formation of 
emulsomes having a small average radius. 
58-59 
Alternatively, the lipid or lipid mixture is dissolved in 
alcoholic solvent and an aliquot of 200, 500, or 600 mL 
fast injected at room temperature, 1 mL syringe into the 
dispersant solution, which contains water or saline 
solution, of 9.8 mL further diluted to 1:50, 9.5 mL diluted 
to 1:20 or 9.8 mL diluted to 1:17, respectively. The 
solution was then vigorously hand-shaken for 20-30 
seconds. 
60-61
 After that the ethanol solution is fast-injected 
in a 5% glucose solution. The vesicles had shown average 
diameter of about 60 nm and may be stable 
foratleastoneweek. 
62-64
  
 
Detergent removal technique
 
In this method, phospholipids and a detergent are mixed 
together to form micellar mixtures. Then the detergent 
removed from the preparation while the micelles 
progressively become richer in phospholipid content and 
finally the lipids come together to form single bilayer 
vesicles. Methods such as dialysis, column 
chromatography, or adsorption onto bio beads can be used 
to remove the detergent from the preparation. The dialysis 
technique was first reported for reconstituting biological 
membranes solubilized with detergents. 
65
 This method is 
applicable for the preparation of emulsomes also. 
Detergents that are commonly used for this purpose are 
those that have high critical micelle concentration (CMC). 
Materials such as sodium cholate, sodium deoxycholate, 
and octylglycoside and other detergents of high CMC (in 
the order of 10- 20 mM) are suitable detergents for this 
work. 
66
 In technique, detergent was removed by a flow 
through dialysis cell from phospholipid detergent mixture. 
It was reported that this technique yielded homogeneous 
population of single layered emulsomes with mean 
diameters of 50-100nm.
67-68
  
Biopharmaceutical aspects 
Emulsomes helps increasing the in-effective luminal drug 
solubility. The presence of lipids in the GI tract stimulates 
an increase in the secretion of bile salts and endogenous 
biliary lipids including phospholipid and cholesterol, 
leading to the formation of bile 
salts/phospholipid/cholesterol intestinal mixed micelles 
and leads increase in the solubilisation capacity of the GI 
tract. However, exogenous lipids into these bile salts 
structures either directly or secondary to digestion, leads to 
swelling of the micellar structures and a further increase in 
solubilisation capacity. 
69
 Therefore, on the stimulation of 
intestinal lymphatic transportation, lipids may enhance the 
extent of lymphatic transport and increase bioavailability 
directly or indirectly via a reduction in first-pass 
metabolism. 
 
Emulsomes may enhance bioavailability by changing the 
biochemical barrier function of the GI tract. It is clear that 
the lipids and triglycrides, which are incorporated in 
emulsomal preparation may attenuate the activity of 
intestinal efflux transporters, as indicated by the p-
glycoprotein efflux pump and may also reduce the extent 
of enterocyte-based metabolism. 
70-71
  
Emulsomes may change the physical barrier function of 
the GI tract. Various combinations of lipids and 
triglycerides have been shown to have permeability 
enhancing properties. 
72-73
 However, passive intestinal 
permeability is not thought to be a major barrier to the 
bioavailability of the majority of poorly water-soluble and 
lipophilic drugs. 
 
Stability aspects of emulsomes 
Emulsomes have the characteristics of both liposomes and 
emulsions; provide the advantages of high loading of 
hydrophobic bioactive compounds in the internal solid 
lipid core and the ability to encapsulate water-soluble 
drugs or antigens in the aqueous compartments of 
surrounding phospholipid layers. 
14
 The pharmaceutically 
stable emulsomes may be formulated in the absence of any 
ionic or non-ionic non-natural synthetic surfactants or 
cosurfactants such as polyoxamers, deoxycholate, 
polysorbates, etc. They are stabilized by the combination 
of relatively high lecithin content and the use of solid lipid 
compositions as the core. 
13
 The particle size distribution 
of emulsomes is based on differential weight percents in 
the range of 10-250 nm, making them suitable for 
parenteral administration by adding in water for injection. 
 
Whereas oral vesicular formulations are generally instable, 
mainly due to leakage and potential destruction in gastric 
fluids. Emulsomes are a dry free-flowing powder when it 
comes in contact with water. The stability problems 
associated with conventional liposomes or other vesicular 
delivery systems are aggregation, susceptibility to 
hydrolysis, and oxidation. These problems may be avoided 
by using emulsomes.
 10-13
 Since emulsomes exist as a dry 
powder and upon hydration they are more suitable for 
developing sustained release formulations for oral 
delivery. 
 
Important factor related to stability is zeta potential; the 
measurement of zeta-potential in electrostatically 
stabilized vesicles is the key factor to understand the 
application of the dispersion and aggregation processes 
and certainly is an important criterion for study of the 
storage stability of these vesicles. 
9-10
 Change in the lipid 
type, increased the absolute value of zeta-potential 
whereas in emulsomes, fats used trilaurin, tristearin, and 
comptriol ATO 888 provide a great negative value of zeta 
potential.
9,10,14
 Therefore, decrease in particle size and zeta 
potential due to high input energy during sonication 
provides stable and highly packed emulsomes. 
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APPLICATION OF EMULSOMES  
Drug targeting 
One of the most useful aspects of emulsomes is their 
ability to target drugs. Emulsomes can be used to target 
drugs to the reticulo-endothelial system. The reticulo-
endothelial system preferentially takes up Emulsomes. The 
uptake of Emulsomal vesicles is controlled by circulating 
serum factors called opsonins. These opsonins mark the 
vesicles for clearance. Such localization of drugs is utilized 
to treat tumors in animals known to metastasize to the liver 
and spleen. This localization of drugs can also be used for 
treating parasitic infections of the liver. [74] Emulsomes 
can also be utilized for targeting drugs to organs other than 
the reticulo-endothelial system. A carrier system (such as 
antibodies) can be attached to vesicles 
totargetthemtospecificorgans. 
75
 
Anti-neoplastic treatment 
Most antineoplastic drugs cause severe side effects. 
Emulsomes can alter the metabolism; prolong circulation 
and half life of the drug, thus decreasing the side effects of 
the drugs. Emulsomal entrapment of Methotrexate showed 
beneficial effects over the unentrapped drugs, such as 
decreased rate of proliferation of the tumor and higher 
plasma levels accompanied by slower elimination. [Table 
2] shows various studies done on emulsomes as delivery 
system. 
76-77
 
Leishmaniasis 
 
Leishmaniasis is a disease in which a parasite of the genus 
Leishmania invades the cells of the liver and spleen. 
Commonly prescribed drugs for the treatment are 
derivatives of antimony (antimonials), which in higher 
concentrations can cause cardiac, liver, and kidney 
damage. Use of emulsome in tests conducted showed that 
it was possible to administer higher levels of the drug 
without triggering the side effects, and thus allowed 
greater efficacy in treatment.
78-79 
  
Use in Biotechnology 
Emulsomes are used in studying immune response due to 
their immunological selectivity, low toxicity, and greater 
stability. They are being used to study the nature of the 
immune response provoked by antigens. The in 
vitro permeation of estradiol from vesicular formulations 
through human stratum corneum was studied. The vesicles 
were composed of non-ionic n-alkyl polyoxyethylene ether 
surfactants. Two mechanisms are proposed to play an 
important role in vesicle-skin interactions, i.e., the 
penetration enhancing effect of surfactant molecules and 
the effect of the vesicular structures caused by their 
adsorption at the stratum corneum- suspension interface. 
80  
FUTURE ASPECTS 
Emulsomes are a promising approach for the formulation 
of drug compounds with poor aqueous solubility with 
varied oral bioavailability. The oral delivery of 
hydrophobic drugs can be made possible by emulsomes, 
which have been shown to substantially improve oral 
bioavailability. Renaissances in the use of emulsomes over 
the past few decades are inviting increasing attention. 
Recent trends are focused on the development of modified 
emulsomal solid or semisolid formulations as an 
alternative to the conventional liquid system. The 
development of emulsomes, however, is still largely 
empirical, and in vitro models that are predictive of oral 
bioavailability enhancement are lacking. There is a need 
for in vitro methods for predicting the dynamic changes 
involving the drug in the gut in order to monitor the 
solubilisation state of the drug in vivo. Attention also needs 
to be paid to the interactions between lipid systems and the 
pharmacologically active substance. The characteristics of 
various lipid formulations also need to be understood, so 
that guidelines can be established that allow identification 
of suitable candidate formulations at an early stage. Future 
research should involve human bioavailability studies as 
well as more basic studies on the mechanisms of action of 
this fascinating and diverse group of formulations.
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